Digest Network Come funziona
Network
/
Società
Sa
Non verificato

Sage Therapeutics, Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VariePsichiatriaSalute

20 comunicati stampa

Guarda tutti i comunicati
30/07/2025
Biotecnologia
Psichiatria
Salute
Farmaceutica
Medicina - Varie
Mercato azionario
Sage Therapeutics Announces Second Quarter 2025 Financial Results
Fonte
Sage Therapeutics, Inc.
Emittente
Business Wire
1.00
0
29/04/2025
Web e Social Network
Telefonia e Varie
Mercato azionario
Biotecnologia
Farmaceutica
Salute
Psichiatria
Assistenza all'Infanzia
Vetrine/Shopping
Sage Therapeutics Announces First Quarter 2025 Financial Results and Highlights Pipeline and Business Updates
Fonte
Sage Therapeutics, Inc.
Emittente
Business Wire
1.00
0
15/04/2025
Web e Social Network
Telefonia e Varie
Finanza
Mercato azionario
Biotecnologia
Farmaceutica
Salute
Sage Therapeutics to Report First Quarter 2025 Financial Results on Tuesday, April 29, 2025
Fonte
Sage Therapeutics, Inc.
Emittente
Business Wire
1.00
0
04/03/2025
Mercato del lavoro
Biotecnologia
Farmaceutica
Salute
Sage Therapeutics Announces R&D Leadership Transition
Fonte
Sage Therapeutics, Inc.
Emittente
Business Wire
1.00
0
11/02/2025
Biotecnologia
Farmaceutica
Salute
Psichiatria
Assistenza all'Infanzia
Vetrine/Shopping
Web e Social Network
Telefonia e Varie
Mercato azionario
Sage Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Highlights Pipeline and Business Updates
Fonte
Sage Therapeutics, Inc.
Emittente
Business Wire
1.00
0
28/01/2025
Biotecnologia
Igiene alimentare
Salute
Farmaceutica
Web e Social Network
Telefonia e Varie
Finanza
Mercato azionario
Sage Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on Tuesday, February 11, 2025
Fonte
Sage Therapeutics, Inc.
Emittente
Business Wire
1.00
0
27/01/2025
Biotecnologia
Farmaceutica
Salute
Sage Therapeutics Board of Directors Initiates Review of Strategic Alternatives and Rejects Biogen’s Unsolicited Acquisition Proposal
Fonte
Sage Therapeutics, Inc.
Emittente
Business Wire
1.00
0
10/01/2025
Scienza
Biotecnologia
Farmaceutica
Sanità
Salute
Sage Therapeutics Confirms Receipt of Unsolicited Nonbinding Acquisition Proposal from Biogen
Fonte
Sage Therapeutics, Inc.
Emittente
Business Wire
1.00
0
26/11/2024
Eventi
Web e Social Network
Biotecnologia
Psichiatria
Salute
Farmaceutica
Sage Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference
Fonte
Sage Therapeutics, Inc.
Emittente
Business Wire
1.00
0
20/11/2024
Psichiatria
Salute
Medicina - Varie
Farmaceutica
Biotecnologia
Industria
Sage Therapeutics Announces Topline Results from the Phase 2 DIMENSION Study of Dalzanemdor (SAGE-718) in the Treatment of Cognitive Impairment Associated with Huntington’s Disease
Fonte
Sage Therapeutics, Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0